Alasdair Bamford, Tiziana Masini, Phoebe Williams, Mike Sharland, Valeria Gigante, Devika Dixit, Hatim Sati, Benedikt Huttner, Yasir Bin Nisar, Bernadette Cappello, Wilson Were, Jennifer Cohn, Martina Penazzato
Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children, and adolescents aged yonger than 19 years, and focusing finite resources on the most appropriate agents for development and paediatric optimisation is urgently needed. In November and December, 2022, following the successes of previous similar disease-focused exercises, WHO convened the first Paediatric Drug Optimisation (PADO) exercise for antibiotics, aiming to provide a shortlist of antibiotics to be prioritised for paediatric research and development, especially for use in regions with the highest burden of disease attributable to serious bacterial infection...
April 19, 2024: Lancet Child & Adolescent Health